AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14680204 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid 10 mg/kg after anaesthetic induction, on bypass, and after protamine at the end of bypass (group B)
Number of subjects: 120
Study 14680204 — intervention group
Group type: COMPARATOR
Intervention: No drug (group A)
Number of subjects: 120
Study 10880793 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa
Number of subjects: 10
Study 10880793 — intervention group
Group type: EXPERIMENTAL
Intervention: Pergolide
Number of subjects: 10
Study 10880793 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched)
Number of subjects: 10
Study 8804799 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fluconazole, 200 mg once daily
Number of subjects: 31
Study 8804799 — intervention group
Group type: COMPARATOR
Intervention: Intravenous amphotericin B, 0.3 mg/kg
Number of subjects: 31
Study 8804799 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 31
Study 8804799 — intervention group
Group type: COMPARATOR
Intervention: Intravenous amphotericin B
Number of subjects: 31
Study 8804799 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fluconazole
Number of subjects: 31
Study 1733187 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium gluconate 1 gm orally four times daily
Number of subjects: 54
Study 1733187 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 1733187 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium gluconate
Number of subjects: 54
Study 6467800 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (rectal infusion at a zero-order rate for 24 hr)
Number of subjects: 6
Study 6467800 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 6
Study 31437754 — intervention group
Group type: EXPERIMENTAL
Intervention: encorafenib 450 mg once daily plus binimetinib 45 mg twice daily
Number of subjects: 570
Study 31437754 — intervention group
Group type: EXPERIMENTAL
Intervention: encorafenib 300 mg once daily
Number of subjects: 570
Study 31437754 — intervention group
Group type: COMPARATOR
Intervention: vemurafenib 960 mg twice daily
Number of subjects: 570
Study 29595687 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycyrrhizae Decoction for Purging Stomach-Fire (GDPSF)
Number of subjects: 0
Study 29595687 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide
Number of subjects: 0
Study 29595687 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of GDPSF and thalidomide
Number of subjects: 0
Study 29595687 — intervention group
Group type: COMPARATOR
Intervention: GDPSF
Number of subjects: 0
Study 27037499 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie information provided in a questionnaire
Number of subjects: 119
Study 27037499 — intervention group
Group type: COMPARATOR
Intervention: Calorie information in a randomized field experiment
Number of subjects: 119
Study 25134860 — intervention group
Group type: EXPERIMENTAL
Intervention: Strict glucose control (90-120 mg/dL)
Number of subjects: 0
Study 25134860 — intervention group
Group type: COMPARATOR
Intervention: Liberal glucose control (121-180 mg/dL)
Number of subjects: 0
Study 25134860 — intervention group
Group type: EXPERIMENTAL
Intervention: Both strict and liberal glucose control
Number of subjects: 0
Study 23185314 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity (HI) training (n = 161, 152 completed)
Number of subjects: 303
Study 23185314 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity (LI) training (n = 142, 136 completed)
Number of subjects: 303
Study 20578377 — intervention group
Group type: EXPERIMENTAL
Intervention: Warming‐reinforcing acupuncture combined with rehabilitation training (group A)
Number of subjects: 80
Study 20578377 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation training (group B)
Number of subjects: 80
Study 18096041 — intervention group
Group type: EXPERIMENTAL
Intervention: PFMT combined with RBT
Number of subjects: 106
Study 18096041 — intervention group
Group type: COMPARATOR
Intervention: PFMT alone
Number of subjects: 106
Study 15510191 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg
Number of subjects: 120
Study 15510191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 12502278 — intervention group
Group type: EXPERIMENTAL
Intervention: I Can Problem Solve (ICPS) program alone
Number of subjects: 655
Study 12502278 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined ICPS and Strengthening Families (SF) program
Number of subjects: 655
Study 12502278 — intervention group
Group type: EXPERIMENTAL
Intervention: SF parent training only
Number of subjects: 655
Study 12502278 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengthening Families (SF) program
Number of subjects: 655
Study 12502278 — intervention group
Group type: COMPARATOR
Intervention: No-treatment controls
Number of subjects: 655
Study 9661398 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Care Assistants (HCAs) in orthopaedic and medical wards
Number of subjects: 0
Study 9661398 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses in wards with HCAs
Number of subjects: 0
Study 9661398 — intervention group
Group type: COMPARATOR
Intervention: Nurses in control wards
Number of subjects: 0
Study 7917368 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron and Lorazepam
Number of subjects: 53
Study 2802124 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2.5 mg/kg
Number of subjects: 32
Study 2802124 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone 5 mg/kg
Number of subjects: 32
Study 8749 — intervention group
Group type: EXPERIMENTAL
Intervention: Dibenzepin (Noveril)
Number of subjects: 0
Study 8749 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 0
Study 7001282 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucametacine
Number of subjects: 40
Study 7001282 — intervention group
Group type: COMPARATOR
Intervention: Phenylbutazone
Number of subjects: 40
Study 31835206 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab beta
Number of subjects: 0
Study 31835206 — intervention group
Group type: COMPARATOR
Intervention: Assuming no censored participants were confirmed
Number of subjects: 0
Study 31835206 — intervention group
Group type: COMPARATOR
Intervention: Assuming all censored participants were confirmed
Number of subjects: 0
Study 31835206 — intervention group
Group type: EXPERIMENTAL
Intervention: Observed rate multiple imputation (ORMI)
Number of subjects: 0
Study 30256198 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (PPI)
Number of subjects: 16
Study 30256198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 27052122 — intervention group
Group type: EXPERIMENTAL
Intervention: Methimazole therapy in subjects with TSH <1.0 μIU/mL
Number of subjects: 293
Study 27052122 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation (untreated) in subjects with TSH <1.0 μIU/mL
Number of subjects: 293
Study 27052122 — intervention group
Group type: COMPARATOR
Intervention: Observation (untreated) in subjects with TSH ≥1.0 μIU/mL
Number of subjects: 293
Study 24581989 — intervention group
Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa
Number of subjects: 1506
Study 24581989 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily recombinant FSH
Number of subjects: 1506
Study 24581989 — intervention group
Group type: COMPARATOR
Intervention: Corifollitropin alfa and Daily recombinant FSH
Number of subjects: 1506
Study 22415232 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 (80, 100, or 120 mg per day on days 1-28, every 42 days, 4 courses)
Number of subjects: 1504
Study 22415232 — intervention group
Group type: COMPARATOR
Intervention: UFT/LV (UFT, 300 mg m(‐2) per day as tegafur; LV, 75 mg per day on days 1-28, every 35 days, 5 courses)
Number of subjects: 1504
Study 19458303 — intervention group
Group type: EXPERIMENTAL
Intervention: Medihoney Antibacterial Wound Gel
Number of subjects: 370
Study 19458303 — intervention group
Group type: COMPARATOR
Intervention: Mupirocin (control)
Number of subjects: 370
Study 17505376 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) group work
Number of subjects: 0
Study 17505376 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 14678367 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced patient participation in treatment choice
Number of subjects: 210
Study 14678367 — intervention group
Group type: COMPARATOR
Intervention: Standardized treatment protocol
Number of subjects: 210
Study 11547358 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-hirudin (polyethylene glycol-hirudin)
Number of subjects: 0
Study 9888616 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol + vitamin E (3200 IU/day)
Number of subjects: 24
Study 9888616 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol alone
Number of subjects: 24
Study 8031480 — intervention group
Group type: EXPERIMENTAL
Intervention: Action toothbrush
Number of subjects: 56
Study 8031480 — intervention group
Group type: COMPARATOR
Intervention: Oral-B toothbrush
Number of subjects: 56
Study 8031480 — intervention group
Group type: EXPERIMENTAL
Intervention: Both brushes
Number of subjects: 56
Study 2691573 — intervention group
Group type: EXPERIMENTAL
Intervention: Clovoxamine (50 mg b.d. to 300 mg max)
Number of subjects: 72
Study 2691573 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (5 mg b.d. to 30 mg max)
Number of subjects: 72
Study 1105692 — intervention group
Group type: EXPERIMENTAL
Intervention: Laminaria tents inserted 14-18 hr before PGF2alpha infusion
Number of subjects: 230
Study 1105692 — intervention group
Group type: EXPERIMENTAL
Intervention: Laminaria tents inserted at the same time as PGF2alpha infusion
Number of subjects: 230
Study 1105692 — intervention group
Group type: COMPARATOR
Intervention: Intra-amniotic PGF2alpha 40 mg
Number of subjects: 230
Study 31836635 — intervention group
Group type: EXPERIMENTAL
Intervention: AM-PICC
Number of subjects: 0
Study 31836635 — intervention group
Group type: COMPARATOR
Intervention: S-PICC
Number of subjects: 0
Study 30653554 — intervention group
Group type: EXPERIMENTAL
Intervention: Water condition (supplementary drinking water provided throughout the day)
Number of subjects: 0
Study 30653554 — intervention group
Group type: COMPARATOR
Intervention: Control condition (normal school conditions without supplementary water)
Number of subjects: 0
Study 30653554 — intervention group
Group type: EXPERIMENTAL
Intervention: Water condition
Number of subjects: 0
Study 30653554 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 28246338 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference book providing weight‐based precalculated doses
Number of subjects: 40
Study 28246338 — intervention group
Group type: COMPARATOR
Intervention: Card providing milligram‐per‐kilogram doses
Number of subjects: 40
Study 25521275 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve growth factor (NGF) injection (1 µg) into tibialis anterior and erector spinae muscles and fasciae
Number of subjects: 8
Study 25521275 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve growth factor (NGF) injection (1 µg)
Number of subjects: 8
Study 25521275 — intervention group
Group type: EXPERIMENTAL
Intervention: Acidic buffer injections (pH 4, 100 µl)
Number of subjects: 8
Study 23142442 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotating platform posterior stabilized total knee arthroplasty (TKA)
Number of subjects: 153
Study 23142442 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinematic subset of subjects
Number of subjects: 153
Study 20878159 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel/cisplatin (DP) as first-line treatment
Number of subjects: 58
Study 20878159 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI as first-line treatment
Number of subjects: 58
Study 20878159 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI as second-line treatment
Number of subjects: 58
Study 20878159 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel/cisplatin (DP) as second-line treatment
Number of subjects: 58
Study 20878159 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm A (DP → FOLFIRI)
Number of subjects: 58
Study 20878159 — intervention group
Group type: COMPARATOR
Intervention: Arm B (FOLFIRI → DP)
Number of subjects: 58
Study 19885944 — intervention group
Group type: EXPERIMENTAL
Intervention: Far-infrared rays (FIR) applied to three acupuncture points (Nei-Kuan (PC6), Shenmen (HT7), Sanyinjiao (SP6)) for 15 minutes twice a week for four weeks
Number of subjects: 70
Study 19885944 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 70
Study 18035955 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.15 microg/kg/min
Number of subjects: 60
Study 18035955 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil 0.1 microg/kg/min
Number of subjects: 60
Study 18035955 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (remifentanil 0.1 microg/kg/min and 0.15 microg/kg/min)
Number of subjects: 60
Study 15277611 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg donepezil daily for 12 weeks
Number of subjects: 134
Study 15277611 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label donepezil (5 mg daily for 6 weeks, then 10 mg daily for 6 weeks)
Number of subjects: 134
Study 15277611 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study 10731625 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 0
Study 10731625 — intervention group
Group type: COMPARATOR
Intervention: D-methamphetamine
Number of subjects: 0
Study 8923850 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox (250 mg, orally)
Number of subjects: 18
Study 8923850 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 1404449 — intervention group
Group type: COMPARATOR
Intervention: Beta-carotene (0, 15, 30, 45, or 60 mg daily for approximately 9 months)
Number of subjects: 45
Study 1404449 — intervention group
Group type: COMPARATOR
Intervention: Beta-carotene (topically applied)
Number of subjects: 45
Study 3888229 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g/day of fish oil (Maxepa)
Number of subjects: 25
Study 3888229 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 g/day of fish oil (Maxepa)
Number of subjects: 25
Study 3888229 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 25
Study 30845754 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fermentable, oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAP)‐gluten free diet (LF‐GFD)
Number of subjects: 0
Study 30845754 — intervention group
Group type: COMPARATOR
Intervention: Regular gluten‐free diet (R‐GFD)
Number of subjects: 0
Study 28777139 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-20 minutes fluid bolus
Number of subjects: 96
Study 28777139 — intervention group
Group type: COMPARATOR
Intervention: 5-10 minutes fluid bolus
Number of subjects: 96
Study 25248816 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin (dual therapy)
Number of subjects: 574
Study 25248816 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone (monotherapy)
Number of subjects: 574
Study 23317474 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Psychotherapy (BPT)
Number of subjects: 256
Study 23317474 — intervention group
Group type: COMPARATOR
Intervention: Pilates (active control)
Number of subjects: 256
Study 23317474 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary outcome
Number of subjects: 256
Study 23317474 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary outcomes
Number of subjects: 256
Study 23317474 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness assessment
Number of subjects: 256
Study 20927557 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive transforaminal lumbar interbody fusion (MiTLIF)
Number of subjects: 52
Study 20927557 — intervention group
Group type: COMPARATOR
Intervention: Open transforaminal lumbar interbody fusion (OTLIF)
Number of subjects: 52
Study 18854801 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural plant extracts for intimate hygiene (Salvia officinalis, Camomilla recutita, Thymus vulgaris) used once or twice a day for four weeks
Number of subjects: 2641
Study 16317014 — intervention group
Group type: EXPERIMENTAL
Intervention: Early chemotherapy (MVP regimen: mitomycin C 8 mg/m2, vinblastine 6 mg/m2, cisplatin 50 mg/m2 or carboplatin AUC 5) every 3 weeks for up to six cycles
Number of subjects: 43
Study 16317014 — intervention group
Group type: COMPARATOR
Intervention: Delayed chemotherapy (initial best supportive care with chemotherapy added at time of symptomatic progression)
Number of subjects: 43
Study 16317014 — intervention group
Group type: EXPERIMENTAL
Intervention: Early chemotherapy (MVP regimen)
Number of subjects: 43
Study 14528069 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (Dex)
Number of subjects: 28
Study 14528069 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF)
Number of subjects: 28
Study 14528069 — intervention group
Group type: COMPARATOR
Intervention: No pretreatment
Number of subjects: 28
Study 10321372 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening (chest x-ray examination and sputum cytology every four months for six years)
Number of subjects: 9211
Study 10321372 — intervention group
Group type: COMPARATOR
Intervention: Usual care (annual chest x-ray examination and sputum cytology)
Number of subjects: 9211
Study 10321372 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening
Number of subjects: 9211
Study 8607237 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate-specific antigen (PSA) measurement and digital rectal examination (DRE) followed by transrectal ultrasonography of the prostate when PSA or DRE is abnormal
Number of subjects: 14554
Study 8607237 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual screening with PSA
Number of subjects: 14554
Study 1750604 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nebulised fentanyl at 318 micrograms/ml
Number of subjects: 30
Study 1750604 — intervention group
Group type: COMPARATOR
Intervention: Inhaled nebulised fentanyl at 159 micrograms/ml
Number of subjects: 30
Study 1750604 — intervention group
Group type: COMPARATOR
Intervention: Inhaled nebulised fentanyl at 64 micrograms/ml
Number of subjects: 30
Study 7128188 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (15 mg per day)
Number of subjects: 9
Study 7128188 — intervention group
Group type: COMPARATOR
Intervention: Imipramine (75 mg per day)
Number of subjects: 9
Study 31170926 — intervention group
Group type: EXPERIMENTAL
Intervention: 90° rotation technique
Number of subjects: 129
Study 31170926 — intervention group
Group type: COMPARATOR
Intervention: Standard technique
Number of subjects: 129
Study 28760278 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized interventions based on Q methodology
Number of subjects: 160
Study 28760278 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment (Control)
Number of subjects: 160
Study 25581062 — intervention group
Group type: EXPERIMENTAL
Intervention: Zambia's Child Grant Program (unconditional cash transfers)
Number of subjects: 0
Study 24416797 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain offset (after experiencing acute physical pain)
Number of subjects: 0
Study 24416797 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain offset
Number of subjects: 0
Study 22587432 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to hand hygiene facilities with short repetitive instruction in hand hygiene every 2 months
Number of subjects: 773
Study 22587432 — intervention group
Group type: COMPARATOR
Intervention: Access to hand hygiene facilities only
Number of subjects: 773
Study 19488607 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (850 mg bid for 90 days)
Number of subjects: 31
Study 19488607 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 17998024 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk beverage
Number of subjects: 10
Study 17998024 — intervention group
Group type: COMPARATOR
Intervention: Fruit-flavored beverage
Number of subjects: 10
Study 15832031 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of donepezil for 12 months
Number of subjects: 50
Study 15832031 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of hypertension (HBP) and periventricular hyperintensities (PVH)
Number of subjects: 50
Study 15832031 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 50
Study 12210644 — intervention group
Group type: EXPERIMENTAL
Intervention: Anorexia nervosa (AN)
Number of subjects: 4185
Study 12210644 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulimia nervosa (BN)
Number of subjects: 4185
Study 12210644 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating disorders not otherwise specified (EDNOS)
Number of subjects: 4185
Study 10323086 — intervention group
Group type: EXPERIMENTAL
Intervention: IgAN
Number of subjects: 27
Study 10323086 — intervention group
Group type: EXPERIMENTAL
Intervention: SHN
Number of subjects: 27
Study 9846856 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg Zn as ZnSO4 daily in fruit juice, Monday to Friday for 6 months)
Number of subjects: 153
Study 9846856 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 153
Study 9846856 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study 1679448 — intervention group
Group type: EXPERIMENTAL
Intervention: Hibiscrub
Number of subjects: 73
Study 1679448 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgiscrub
Number of subjects: 73
Study 1679448 — intervention group
Group type: EXPERIMENTAL
Intervention: Uniscrub
Number of subjects: 73
Study 1679448 — intervention group
Group type: EXPERIMENTAL
Intervention: Macrocide
Number of subjects: 73
Study 6351148 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback Group (EMG and thermal biofeedback with relaxation strategies)
Number of subjects: 30
Study 6351148 — intervention group
Group type: COMPARATOR
Intervention: Waiting List Control Group
Number of subjects: 30
Study 6351148 — intervention group
Group type: EXPERIMENTAL
Intervention: Benson's Relaxation Response procedure
Number of subjects: 30
Study 29363437 — intervention group
Group type: EXPERIMENTAL
Intervention: Full presentation of automated procedural guidance
Number of subjects: 0